Mildly obese metabolic syndrome subjects
Conditions
Interventions
PGX is taken for 97 days.
Placebo is taken for 97 days.
Sponsors
TTC
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Males and females aged 20 to 65 (2) Those with BMI ranging between 25 and 30 at the time of selection visit (3) Those with body weight below 100 kg
Exclusion criteria
Exclusion criteria: (1) Those exercising to slim down, those taking health foods for dieting, or who are taking FOSHU or health foods in relation to body mass (2) Those taking medicines, FOSHU or health foods possibly to affect the levels of serum lipids and blood sugar (3) Those under treatment for hyperlipemia, diabetes or obesity (4) Those who may possibly develop allergic reactions associated with the test products (5) Those having a disease necessitating regular medication or a history of serious diseases for which medication was needed (6) Those participating in another clinical study at the beginning of this study or who are contemplating entering into one during the course of this study (7) Those who are pregnant or breastfeeding during the study period (8) Those who are judged by the principal investigator as inadequate for this study for any other reasons
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| BMI (body weight), waist and hip circumferences and CT (areas of body mass and subcutaneous fat) | — |
Secondary
| Measure | Time frame |
|---|---|
| serum lipids (TG, TC, HDL-C and LDL-C), OGTT values (blood sugar and insulin), BP (systolic and diastolic) and pulse rate | — |
Countries
Japan
Contacts
Public ContactMuneaki Iizuka
Total Technological Consultant Co., Ltd.(TTC) Clinical Research Planning Dept.
Outcome results
None listed